Tci Wealth Advisors, Inc. Arcus Biosciences, Inc. Transaction History

Tci Wealth Advisors, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$15.96 - $23.15 $31 - $46	-2 Reduced 50.0%	2 $0
Q4 2022 Feb 06, 2023	BUY	$19.7 - $35.71 $39 - $71	2 Added 100.0%	4 $0
Q3 2022 Nov 08, 2022	BUY	$23.23 - $30.07 $46 - $60	2 New	2 $0
Q2 2022 Jul 19, 2022	SELL	$17.23 - $37.73 $2,205 - $4,829	-128 Closed	0 $0
Q1 2022 Apr 29, 2022	SELL	$28.92 - $41.83 $86 - $125	-3 Reduced 2.29%	128 $4,000
Q4 2021 Jan 24, 2022	BUY	$31.38 - $48.47 $878 - $1,357	28 Added 27.18%	131 $5,000
Q3 2021 Oct 29, 2021	BUY	$26.93 - $37.68 $2,773 - $3,881	103 New	103 $4,000
Q2 2021 Aug 02, 2021	SELL	$22.75 - $35.77 $1,228 - $1,931	-54 Closed	0 $0
Q1 2021 Apr 29, 2021	BUY	$26.16 - $41.39 $1,412 - $2,235	54 New	54 $2,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.